Why
invest in Meliodays?
Meliodays is reimagining uterine health by combining proven drugs and devices with established clinical pathways to develop targeted local therapeutics.
Underserved market with high unmet demand
Dysmenorrhea impacts up to 85% of women globally, with 38% reporting pain so severe that it disrupts daily life¹
Validation studies with 800 patients and 100 gynecologists confirm a treatment gap in current standards of care²
De-risked preclinical and clinical roadmap
~30 years of established Celecoxib safety and efficacy data
Approved IUD frame with a decades-long safety record
Low-barrier beachhead indication
Dysmenorrhea as the first target indication enables straightforward trial enrollment, lower cost, and reduced trial complexity
Option to get to a First-in-Human trial once safety data is available
Precedent exists on workflow and reimbursement
Identical workflow in OBGYN settings reduces adoption barriers in clinical settings
Reimbursement coverage follows the hormonal IUD precedent for heavy menstrual bleeding (HMB) as a therapeutic indication
References:
1 Schoep, M. E., et al. (2019). "The impact of menstrual symptoms on everyday life: a survey among 42,879 women." Am J Obstet Gynecol 220(6): 569.e561–569.e567
2 Meliodays Period Pain Report, 2024 (N.800 women in the US and Germany)
DEVELOPMENT TIMELINE
HOW TO INVEST
Professional Investors
Request a deck, email us at ir@meliodays.com
Impact Investors
Participate via Capacura starting at €1,000.
Frequently Asked Questions (FAQ)
-
MelioOne® is designed for the significant portion of women with severe dysmenorrhea who cannot use existing treatments due to medical contraindications or prefer not to use them due to systemic or hormonal side effects. These women, they are currently stuck in a loop of incomplete relief.
-
Current competitors include oral NSAIDs, hormonal contraceptives, and hormonal IUDs with new entrants developing non-hormonal solutions.
However, MelioOne® is the only solution that combines non-hormonal pain relief with a long-acting intrauterine platform. -
We bring together expertise across gynecology, polymer science, venture capital, finance, and brand building with an insider view of primary and secondary dysmenorrhea.
-
The dysmenorrhea market is currently around $9B and is projected to reach $12 billion by 2030, with a 7-9% CAGR.
-
Capital, urgency, and viable pathways are aligning. Women’s health investment hit ~$2.6B in 2024 (SVB), signaling sustained momentum in FemTech.
Philanthropic catalysts are amplifying this: Pivotal’s $250M open call and the Gates Foundation’s $2.5B through 2030 specifically target underfunded areas like menstrual and gynecological health. Heightened public attention following restrictive policies adds tailwinds to adoption and policy focus.

